Non Hodgkin Lymphoma Clinical Trial

Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy

Summary

Purpose of Phase II study for B-cell lymphoma using PS341: Evaluate efficacy and toxicity of bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

View Full Description

Full Description

Patients were stratified, based on preclinical data, into arm A (mantle-cell lymphoma) or arm B (other B-cell lymphomas) without limitation in number of prior therapies. Bortezomib was administered as an intravenous push (1.5 mg/m2) on days 1, 4, 8, and 11 every 21 days for a maximum of six cycles.

View Eligibility Criteria

Eligibility Criteria

INCLUSION:

Relapsed or Refractory B cell lymphoma.
Zubrod status Measurable disease.
No anti-cancer treatment within past 3 weeks.
ANC >= 1500/uL, Plt >/= 50,000, Bilirubin <2 mg/dL, SGPT <2.5xULN, creatinine <2. Patients with ANC>/1000, PLT>/30000 will be eligible if due to massive splenomegaly and/or BM involvement.
HIV negative.
No active CNS lymphoma.
No serious intercurrent illness, active infections or cancer except basal cell carcinoma of the skin or in situ cervical carcinoma.
Not eligible for treatment of a higher priority. Patients may be entered before BMT.
No pregnancy & age bearing females must be practicing adequate contraception.
Age > 16.

EXCLUSION:

Patients with platelets <30x10(9)/L within 14 days before enrollment.
Patients with ANC<1.0 x10(9)/L within 14 days before enrollment.
Patients with peripheral neuropathy >/= grade 3 within 14 days before enrollment.

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 2

Estimated Enrollment:

60

Study ID:

NCT00038571

Recruitment Status:

Completed

Sponsor:

M.D. Anderson Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

UT MD Anderson Cancer Center
Houston Texas, 77030, United States

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 2

Estimated Enrollment:

60

Study ID:

NCT00038571

Recruitment Status:

Completed

Sponsor:


M.D. Anderson Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider